• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • INT
    • US
    • FR
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

by Elizabeth | Oct 17, 2024 | News

Major New Study Presented at the World’s Largest Gastroenterology Congress Validation of Mauna Kea’s Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity Paris and Boston, October 17, 2024 – 08:00 a.m. CEST – Mauna Kea Technologies...
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales

Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales

by Elizabeth | Oct 15, 2024 | News

Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses   Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe   Official Launch of the Food Intolerance Platform CellTolerance® ...
Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

by Elizabeth | Sep 16, 2024 | News

Recent clinical study published in Journal of Thoracic Disease supports the combination of Cellvizio with Electromagnetic Navigation Bronchoscopy to improve diagnosis and treatment of lung cancer  Cellvizio’s sensitivity of 96.43% and specificity of 100% in...
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

by Elizabeth | Sep 10, 2024 | News

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® Formal letter requests coverage of Cellvizio and its dedicated category I CPT Codes to significantly enhance early detection of Barrett’s Esophagus...
Viszeralmedizin (Deutsche Gesellschaft für Gastroenterologie – DGVS) – Leipzig, Deutschland

Viszeralmedizin (Deutsche Gesellschaft für Gastroenterologie – DGVS) – Leipzig, Deutschland

by Elizabeth | Aug 21, 2024 | Events

30 SEP-05 OKT Die Viszeralmedizin ist der größte Kongress für Gastroenterologie und Viszeralchirurgie im deutschsprachigen Raum. Informieren Sie sich hier über das Programm Viszeralmedizin...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan
  • Mauna Kea Technologies Reaches a Key Milestone in Its Financial Restructuring 
  • Mauna Kea Technologies Announces 2025 Half-Year Results 
  • Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan
  • Mauna Kea Technologies and Endotherapeutics Announce Cellvizio® First Australian Orders, Advancing CellTolerance® Commercial Expansion 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookies policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}